Parkinson's Disease Market Research Analysis and Forecast, 2025-2035, Featuring Key Players - AbbVie, Merck & Co., GlaxoSmithKline, Novartis, and Teva Pharmaceutical - ResearchAndMarkets.com

The "Parkinson's Disease Market - A Global and Regional Analysis: Focus on Drug Class, Country, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.

As Parkinson's disease is a progressive condition, there is a significant opportunity for companies to capitalize on the demand for treatments that not only manage symptoms but also slow or halt disease progression. With ongoing advancements in gene therapies, stem cell-based treatments, and biologic drugs, the competition is intensifying, as companies strive to offer more effective, personalized, and affordable solutions to meet the growing needs of patients. The market is also being shaped by the rising prevalence of Parkinson's disease, driven in part by the global aging population, making it a critical area for investment and innovation.

The global Parkinson's disease market is highly competitive, with several major pharmaceutical companies leading the way in the development of innovative treatments. The global Parkinson's disease (PD) market is highly competitive, with several major pharmaceutical and biotechnology companies vying to develop and commercialize effective treatments for the disease.

These companies are focused on both symptomatic management and disease-modifying therapies, with a strong emphasis on innovation. Some of the key players in the market include AbbVie, Inc., Merck & Co., Inc., GlaxoSmithKline (GSK), Novartis AG, and Teva Pharmaceutical Industries Ltd. These companies compete through a combination of novel drug formulations, advanced delivery systems, and surgical interventions like deep brain stimulation (DBS).

One of the key drivers of the Parkinson's disease (PD) market is the advancement in treatment options, particularly the development of disease-modifying therapies. While current treatments primarily focus on managing symptoms, there is a growing emphasis on targeting the underlying causes of Parkinson's, such as the loss of dopamine-producing neurons. Innovative treatments like gene therapy, cell-based therapies, and novel drug formulations that aim to slow or halt disease progression are generating significant interest in the market.

Additionally, the increasing prevalence of Parkinson's disease, driven by an aging global population, is fuelling demand for effective therapies. As more people are diagnosed, the need for new and improved treatments continues to grow, driving research and investment into Parkinson's disease therapies. Moreover, advances in diagnostics that enable earlier detection and better disease monitoring are also helping to increase market opportunities for new treatments.

Despite the growth of the Parkinson's disease (PD) market, several challenges continue to hinder its expansion and overall effectiveness. One major issue is the lack of a cure, as current treatments primarily focus on symptom management rather than halting or reversing the disease. While levodopa and other medications can alleviate motor symptoms, they do not address the underlying neurodegeneration or slow disease progression. Another challenge is the side effects of long-term treatment, especially with levodopa, which can lead to motor fluctuations and dyskinesia (involuntary movements) over time.

Additionally, high treatment costs for advanced therapies, such as gene therapy or deep brain stimulation (DBS), create significant financial barriers for patients, limiting access to cutting-edge treatments, particularly in lower-income regions. The complexity of early diagnosis and lack of biomarkers for Parkinson's also complicates the timely initiation of treatment. Furthermore, there is a limited understanding of the exact causes of the disease, making it difficult to develop disease-modifying therapies. Finally, the aging global population is driving an increased incidence of Parkinson's, placing added pressure on healthcare systems to provide adequate care and treatment options.

Companies Featured

• GlaxoSmithKline
• Merck & Co., Inc.
• AbbVie, Inc.
• Boehringer Ingelheim
• UCB S.A.
• Teva Pharmaceutical Industries Ltd.
• Bausch Health
• Acadia Pharmaceuticals
• Lundbeck
• Amneal Pharmaceuticals LLC
• Mitsubishi Tanabe Pharma

Key Topics Covered:

1. Global Parkinson's Disease Market: Industry Outlook

1.1 Introduction

1.2 Market Trends

1.3 Epidemiology Analysis

1.4 Regulatory Framework

1.5 Clinical Trial Analysis

1.6 Market Dynamics

1.6.1 Impact Analysis

1.6.2 Market Drivers

1.6.3 Market Challenges

1.6.4 Market Opportunities

2. Global Parkinson's Disease Market, by Drug Class, ($Million), 2023-2035

2.1 Overview

2.2 MAO-B Inhibitors

2.3 COMT inhibitors

2.4 Anticholinergics

2.5 Others

3. Global Parkinson's Disease Market (Region), ($Million), 2023-2035

3.1 North America

3.1.1 Key Findings

3.1.2 Market Dynamics

3.1.3 Market Sizing and Forecast

3.1.3.1 North America Parkinson's Disease Market, by Country

3.1.3.1.1 U.S.

3.1.3.1.2 Canada

3.2 Europe

3.2.1 Key Findings

3.2.2 Market Dynamics

3.2.3 Market Sizing and Forecast

3.2.3.1 Europe Parkinson's Disease Market, by Country

3.2.3.1.1 Germany

3.2.3.1.2 U.K.

3.2.3.1.3 France

3.2.3.1.4 Italy

3.2.3.1.5 Spain

3.2.3.1.6 Rest-of-Europe

3.3 Asia Pacific

3.3.1 Key Findings

3.3.2 Market Dynamics

3.3.3 Market Sizing and Forecast

3.3.3.1 Asia Pacific Parkinson's Disease Market, by Country

3.3.3.1.1 China

3.3.3.1.2 Japan

3.3.3.1.3 India

3.3.3.1.4 South Korea

3.3.3.1.5 Australia

3.3.3.1.6 Rest-of- Asia Pacific

3.4 Rest of the World

3.4.1 Key Findings

3.4.2 Market Dynamics

3.4.3 Market Sizing and Forecast

4. Global Parkinson's Disease Market: Competitive Landscape and Company Profiles

4.1 Key Development and Strategies

4.1.1 Mergers and Acquisitions

4.1.2 Synergistic Activities

4.1.3 Business Expansions and Funding

4.1.4 Product Launches and Approvals

4.1.5 Other Activities

4.2 Company Profiles

4.2.1 Overview

4.2.2 Top Products / Product Portfolio

4.2.3 Top Competitors

4.2.4 Target Customers/End-Users

4.2.5 Key Personnel

4.2.6 Analyst View

5. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/u84a3e

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250613448272/en/

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.